Compugen's Q2 Revenues Rise on Collaboration Fees | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported that its second-quarter revenues increased to $800,000 from $225,000, which the firm attributed to initial fees and research revenues from certain collaborations.

The Tel Aviv, Israel-based drug discovery informatics and drug development firm posted a net loss of $896,000, or $.03 per share, for the three-month period ended June 30, compared to a profit of $2.4 million, or $.08 per share for Q2 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.